MOTS-c: Evidence, Legal Status, and Safety
MOTS-c is a mitochondrial-derived peptide marketed for metabolic health, cellular energy, and anti-aging, but it has not been tested for efficacy in humans. The one completed human study is a discontinued Phase 1a/1b safety trial of a related analog (CB411), not the product actually sold as “MOTS-c.” On 23 Jul 2026, an FDA advisory committee recommended it for compounding, but nothing is legal today.
Understand what's actually being sold A 16-amino-acid mitochondrial-derived peptide (MDP), encoded by a segment of mitochondrial DNA; rises naturally with exercise and is promoted for mitochondrial function, metabolic health, bone health, and anti-aging.
The marketing spans several distinct claims (metabolic, bone, longevity) that are not equally supported.
See what the human evidence actually is Human research is almost entirely observational (measuring naturally occurring MOTS-c levels), not interventional. The one completed human trial (ClinicalTrials.gov NCT03998514) tested a related analog, CB411, for safety and pharmacokinetics only, not efficacy, and the sponsor's clinical program was discontinued.
An observational association and a discontinued safety trial of a different, related molecule do not establish that the product sold as MOTS-c works for any marketed use.
Know where it actually stands Not FDA-approved for any human use; sold as an unregulated research chemical. On 23 Jul 2026 the FDA's Pharmacy Compounding Advisory Committee recommended MOTS-c for compounding (reported 7-5 by trade press) for obesity and osteoporosis specifically. That recommendation is advisory only: nothing became legal, and formal rulemaking has not started.
A favorable advisory vote is not an approval, and the reviewed use (obesity, osteoporosis) is not the anti-aging or performance use it is marketed for.
Know the real risk No completed human safety trial of the product actually sold as MOTS-c exists. Standard unregulated-sourcing risk applies: no purity or sterility guarantee from any authority.
Manipulating a metabolic and mitochondrial signaling pathway with an unstudied dose carries unknown, unquantified risk.
Most human research on MOTS-c is observational, measuring people's own naturally occurring levels rather than testing an injected or synthetic dose.
View sources
MOTS-c Analog CB411 in Healthy Volunteers and Adults With Obesity/Fatty Liver Disease (ClinicalTrials.gov NCT03998514, Phase 1a/1b, discontinued)
MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases
MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering MOTS-c who wants the honest evidence before discussing it with a clinician
- Readers who have seen "exercise mimetic" or anti-aging claims and want the actual trial evidence
- Readers comparing MOTS-c to FDA-approved peptides like semaglutide or tesamorelin
Cautions
- Not FDA-approved for any human use; sold as an unregulated research chemical with no purity or sterility guarantee.
- Human safety and efficacy data on the product actually sold as MOTS-c is essentially absent; the one related human trial tested a different analog for safety only, not efficacy.
- The FDA's 23 Jul 2026 advisory recommendation was for obesity and osteoporosis, not the anti-aging or exercise-mimetic claims it is marketed for, and it did not make MOTS-c legal.
- Educational only, not medical advice.